Greenland Mines wins Australian patent for Klotho gene therapy

Greenland Mines Ltd (Nasdaq: GRML) announced that IP Australia has granted Australian Patent No. 2023252508, entitled "Treatment of Neuromuscular Diseases via Gene Therapy that Expresses Klotho Protein," covering technology exclusively licensed by the company's Biotech Division.

The technology was developed by researchers at Universitat Autònoma de Barcelona and collaborating institutions. The patent protects the use of a human gene therapy employing a muscle-cell specific promoter linked to a nucleic acid gene sequence encoding the human Klotho s-KL protein for treating motor impairment.

Patent claims cover neuronal cells and induced pluripotent stem cells containing the muscle-cell specific promoter and s-KL nucleic acid gene sequence, as well as cellular delivery systems including adeno-associated viral vectors and non-viral vectors with muscle-cell and motor neuron-cell tropism.

The patent relates to the company's KLTO-202 program, which targets ALS and other neuromuscular diseases. Neuromuscular diseases referenced in the announcement include spinal muscular atrophy, Charcot-Marie-Tooth disease, multiple sclerosis, muscular dystrophies, and peripheral neuropathies, among others.

CEO Dr. Joseph Sinkule said the patent "strengthens the intellectual property protecting our approach" and provides "an important foundation as we continue advancing KLTO-202 toward clinical development."

Greenland Mines operates two divisions: a Mining division focused on projects in Greenland, and a Biotech division centered on the Klotho therapeutic platform.

You May Also Be Interested In

• Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
• Sigma Lithium faces $540,000 in fines, begins TAC talks in Brazil
• Five Below reports cybersecurity breach via social engineering